#33Growth Hormone & Body Composition
Sermorelin
growth-hormone-releasing-hormone analogue
Evidence: other human studyReviewed 2026-07-25
Investigated uses
- No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.
Mechanism and hypotheses
- Sermorelin is GHRH(1-29) amide and stimulates pituitary growth-hormone secretion.
- Hypothesized: Current anti-aging and body-composition uses are not supported by a current FDA-approved sermorelin product identified in this review.
Human evidence
- No qualifying controlled human efficacy study for the exact catalog identity/formulation was identified in this review. Limitations: This is a bounded search conclusion, not proof that no report exists; identity, language and indexing limitations may apply.
Safety highlights
- Unknown or insufficiently characterized for the exact catalog product.
- Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.
Regulatory context
No FDA-approved product matching the exact catalog presentation was identified in this review.
Sources used for this entry
- Sermorelin human evidence search — PubMed
- PubMed search: Sermorelin — PubMed
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency